melatonin has been researched along with Central Nervous System Disease in 15 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melatonin is an important neuroprotective factor and its receptors are expressed in the fetal brain." | 6.53 | Melatonin in Pregnancy: Effects on Brain Development and CNS Programming Disorders. ( Assunção Salustiano, EM; Sagrillo-Fagundes, L; Soliman, A; Vaillancourt, C; Yen, PW, 2016) |
| "Melatonin was associated with earlier waking times than placebo (29." | 2.77 | Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial. ( Allport, T; Appleton, R; Choonara, I; Edmond, A; Gamble, C; Gringras, P; Jones, AP; Montgomery, P; Sutcliffe, A; Whitehouse, WP; Wiggs, L; Williamson, PR, 2012) |
| "Melatonin is a hormone produced in and secreted by the pineal gland." | 2.72 | The Effect of Melatonin Modulation of Non-coding RNAs on Central Nervous System Disorders: An Updated Review. ( Chen, S; Fang, Y; Lu, J; Luo, Y; Mei, S; Zhang, J, 2021) |
| "Melatonin is an important hormone regulating circadian rhythm, neuroprotection and neuroimmune processes." | 2.61 | The evolutionarily conserved role of melatonin in CNS disorders and behavioral regulation: Translational lessons from zebrafish. ( Amstislavskaya, TG; Bashirzade, A; de Abreu, MS; Demin, KA; Dos Santos, BE; Genario, R; Giacomini, ACVV; Kalueff, AV; Marchiori, NI; Volgin, AD, 2019) |
| "Melatonin is an important neuroprotective factor and its receptors are expressed in the fetal brain." | 2.53 | Melatonin in Pregnancy: Effects on Brain Development and CNS Programming Disorders. ( Assunção Salustiano, EM; Sagrillo-Fagundes, L; Soliman, A; Vaillancourt, C; Yen, PW, 2016) |
| " The optimal dosage and timing of drug administration is still unclear." | 2.40 | Melatonin: therapeutic use in sleep disorders. ( Chase, JE; Gidal, BE, 1997) |
| "Melatonin was recently reported to be an effective free radical scavenger and antioxidant." | 2.40 | Oxidative damage in the central nervous system: protection by melatonin. ( Reiter, RJ, 1998) |
| "In primary or no-comorbid insomnia, only a 2 mg dose of slow release MEL, 1 to 2 hours before bedtime, over a period of 3 to 12 weeks, is recommended." | 1.62 | Melatonin (MEL) and its use in neurological diseases and insomnia: Recommendations of the French Medical and Research Sleep Society (SFRMS). ( Kilic-Huck, U; Quera-Salva, MA; Vecchierini, MF, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, J | 1 |
| Luo, Y | 1 |
| Mei, S | 1 |
| Fang, Y | 1 |
| Zhang, J | 1 |
| Chen, S | 1 |
| Vecchierini, MF | 1 |
| Kilic-Huck, U | 1 |
| Quera-Salva, MA | 1 |
| Tamtaji, OR | 1 |
| Mirhosseini, N | 1 |
| Reiter, RJ | 3 |
| Azami, A | 1 |
| Asemi, Z | 1 |
| Genario, R | 1 |
| Giacomini, ACVV | 1 |
| Demin, KA | 1 |
| Dos Santos, BE | 1 |
| Marchiori, NI | 1 |
| Volgin, AD | 1 |
| Bashirzade, A | 1 |
| Amstislavskaya, TG | 1 |
| de Abreu, MS | 1 |
| Kalueff, AV | 1 |
| Sagrillo-Fagundes, L | 1 |
| Assunção Salustiano, EM | 1 |
| Yen, PW | 1 |
| Soliman, A | 1 |
| Vaillancourt, C | 1 |
| Anderson, G | 1 |
| Yu, X | 1 |
| Li, Z | 1 |
| Zheng, H | 1 |
| Ho, J | 1 |
| Chan, MT | 1 |
| Wu, WK | 1 |
| Eynan, M | 1 |
| Biram, A | 1 |
| Mullokandov, M | 1 |
| Kronfeld-Schor, N | 1 |
| Paz-Cohen, R | 1 |
| Menajem, D | 1 |
| Arieli, Y | 1 |
| Guven, A | 1 |
| Yavuz, O | 1 |
| Cam, M | 1 |
| Comunoglu, C | 1 |
| Sevi'nc, O | 1 |
| Lerchl, A | 1 |
| Gringras, P | 1 |
| Gamble, C | 1 |
| Jones, AP | 1 |
| Wiggs, L | 1 |
| Williamson, PR | 1 |
| Sutcliffe, A | 1 |
| Montgomery, P | 1 |
| Whitehouse, WP | 1 |
| Choonara, I | 1 |
| Allport, T | 1 |
| Edmond, A | 1 |
| Appleton, R | 1 |
| Bruguerolle, B | 1 |
| Chase, JE | 1 |
| Gidal, BE | 1 |
| Arushanian, EB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson's Disease[NCT04287543] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2021-05-31 | Withdrawn (stopped due to Due to the COVID-19 pandemic, we were unable to begin the study) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for melatonin and Central Nervous System Disease
| Article | Year |
|---|---|
The Effect of Melatonin Modulation of Non-coding RNAs on Central Nervous System Disorders: An Updated Review.
Topics: Central Nervous System Diseases; Humans; Melatonin; MicroRNAs; RNA, Long Noncoding; RNA, Untranslate | 2021 |
Melatonin, a calpain inhibitor in the central nervous system: Current status and future perspectives.
Topics: Animals; Calpain; Central Nervous System; Central Nervous System Diseases; Cysteine Proteinase Inhib | 2019 |
The evolutionarily conserved role of melatonin in CNS disorders and behavioral regulation: Translational lessons from zebrafish.
Topics: Animals; Behavior, Animal; Brain; Central Nervous System Diseases; Disease Models, Animal; Humans; M | 2019 |
Melatonin in Pregnancy: Effects on Brain Development and CNS Programming Disorders.
Topics: Antioxidants; Brain; Central Nervous System Diseases; Female; Fetus; Humans; Melatonin; Neuroprotect | 2016 |
Protective roles of melatonin in central nervous system diseases by regulation of neural stem cells.
Topics: Animals; Cell Differentiation; Central Nervous System Diseases; Humans; Melatonin; Neural Stem Cells | 2017 |
[Interactions of melatonin with the central nervous system].
Topics: Central Nervous System; Central Nervous System Diseases; Circadian Rhythm; Humans; Melatonin; Neurot | 2006 |
Melatonin: therapeutic use in sleep disorders.
Topics: Adult; Aged; Central Nervous System Diseases; Circadian Rhythm; Female; Humans; Male; Melatonin; Mid | 1997 |
Oxidative damage in the central nervous system: protection by melatonin.
Topics: Animals; Antioxidants; Central Nervous System Diseases; Disease Models, Animal; Free Radical Scaveng | 1998 |
[Brain rhythm-organizing structures and pharmacological effect].
Topics: Animals; Antidepressive Agents; Central Nervous System Diseases; Circadian Rhythm; Emotions; Humans; | 2000 |
1 trial available for melatonin and Central Nervous System Disease
| Article | Year |
|---|---|
Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial.
Topics: Adolescent; Central Nervous System Depressants; Central Nervous System Diseases; Child; Child Behavi | 2012 |
5 other studies available for melatonin and Central Nervous System Disease
| Article | Year |
|---|---|
Melatonin (MEL) and its use in neurological diseases and insomnia: Recommendations of the French Medical and Research Sleep Society (SFRMS).
Topics: Central Nervous System Diseases; Circadian Rhythm; Humans; Melatonin; Quality of Life; Sleep; Sleep | 2021 |
Editorial: The Kynurenine and Melatonergic Pathways in Psychiatric and CNS Disorders.
Topics: Central Nervous System Diseases; Humans; Kynurenine; Melatonin; Mental Disorders; Signal Transductio | 2016 |
The transition from day-to-night activity is a risk factor for the development of CNS oxygen toxicity in the diurnal fat sand rat (Psammomys obesus).
Topics: Animals; Antioxidants; Biological Clocks; Central Nervous System Diseases; Circadian Rhythm; Gerbill | 2017 |
Central nervous system complications of diabetes in streptozotocin-induced diabetic rats: a histopathological and immunohistochemical examination.
Topics: Animals; Antioxidants; Brain Chemistry; Central Nervous System Diseases; Cerebellum; Cerebral Cortex | 2009 |
Treatment of sleep disorders with melatonin.
Topics: Central Nervous System Diseases; Developmental Disabilities; Female; Humans; Male; Melatonin; Sleep; | 2012 |